Molecular biology evaluation of the analyzed Ph-MPD patients
| . | PV . | ET . |
|---|---|---|
| No. of patients | 13 | 42 |
| Females | 7 | 31 |
| JAK2 analysis | ||
| V617F/wild type | 12/1 | 26/16 |
| Mean allele burden, % | 69 ± 26 | 37 ± 19 |
| Allele burden more than 50% (%) | 10 (83) | 5 (19) |
| Allele burden more than 80% (%) | 6 (50) | 0 |
| No. of patients with an available clonality pattern (%) | 4 | 18 |
| Monoclonal | 2 (50) | 6 (33) |
| Polyclonal | 0 (0) | 8 (44) |
| Skewing | 2 (50) | 4 (22) |
| . | PV . | ET . |
|---|---|---|
| No. of patients | 13 | 42 |
| Females | 7 | 31 |
| JAK2 analysis | ||
| V617F/wild type | 12/1 | 26/16 |
| Mean allele burden, % | 69 ± 26 | 37 ± 19 |
| Allele burden more than 50% (%) | 10 (83) | 5 (19) |
| Allele burden more than 80% (%) | 6 (50) | 0 |
| No. of patients with an available clonality pattern (%) | 4 | 18 |
| Monoclonal | 2 (50) | 6 (33) |
| Polyclonal | 0 (0) | 8 (44) |
| Skewing | 2 (50) | 4 (22) |
Ph-MPD indicates Philadelphia-negative myeloproliferative disease; PV, polycythemia vera; and ET, essential thrombocythemia.